Literature DB >> 1435228

The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl.

C Marguerie1, C C Bunn, J Copier, R M Bernstein, J M Gilroy, C M Black, A K So, M J Walport.   

Abstract

The clinical and laboratory features of 32 patients with anti-PM-Scl were studied. Patients with this rare autoantibody suffered from a homogenous overlap connective tissue disease defined by Raynaud phenomenon (32/32), features of scleroderma (31/32), arthritis (31/32, erosive in 9/32), myositis (28/32), lung restriction (25/32), calcinosis (15/32), and sicca (11/32). Significant renal and neurologic involvement was uncommon. All patients examined (22/22) had HLA-DR3, and 50% of these patients were homozygous. Our patients responded favorably to moderate immunosuppression and, with therapy, the disease generally has a good prognosis; over 50% of our series (17/32) remained well on minimal or no immunosuppression after a median follow-up of 8 years.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1435228     DOI: 10.1097/00005792-199211000-00001

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  30 in total

Review 1.  Systemic sclerosis: an autoantibody mosaic.

Authors:  C C Bunn; C M Black
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 3.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

4.  Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.

Authors:  C Rigamonti; L M Shand; M Feudjo; C C Bunn; C M Black; C P Denton; A K Burroughs
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

Review 5.  How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?

Authors:  O Meyer
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 6.  Scleromyositis: a scleroderma/polymyositis overlap syndrome.

Authors:  S Jablonska; M Blaszczyk
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

7.  Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.

Authors:  Rebecca De Lorenzo; Iago Pinal-Fernandez; Wilson Huang; Jemima Albayda; Eleni Tiniakou; Cheilonda Johnson; Jose C Milisenda; Maria Casal-Dominguez; Andrea M Corse; Sonye K Danoff; Lisa Christopher-Stine; Julie J Paik; Andrew L Mammen
Journal:  Neurology       Date:  2018-05-04       Impact factor: 9.910

8.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

9.  Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.

Authors:  Katharina Hanke; Claudia S Brückner; Cornelia Dähnrich; Dörte Huscher; Lars Komorowski; Wolfgang Meyer; Anthonia Janssen; Marina Backhaus; Mike Becker; Angela Kill; Karl Egerer; Gerd R Burmester; Falk Hiepe; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

10.  Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.

Authors:  Jennifer C Parker; Rufus W Burlingame; Christopher C Bunn
Journal:  J Autoimmune Dis       Date:  2009-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.